Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy
ABSTRACT Limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM) are autosomal recessive disorders caused by mutations in the dysferlin gene on chromosome 2p13. The authors studied a large Russian family with both LGMD2B and MM. All affected individuals, as well as one preclinical boy with dystrophic changes on muscle biopsy, were found to be homozygous for a novel dysferlin mutation, TG573/574AT (Val67Asp). This finding supports the view that additional factors (e.g., modifier genes) contribute to the phenotypic expression of causative mutations in dysferlinopathies.
- SourceAvailable from: Katherine R Sadleir
[Show abstract] [Hide abstract]
- "A point mutation, I67D, was engineered into the myoferlin C2A domain. In dysferlin, the homologous mutation (V67D) results in muscular dystrophy in humans (Illarioshkin et al., 2000), and reduces calcium-sensitive phospholipid binding in vitro (Davis et al., 2002). A similar point mutation, I67D, in myoferlin C2A also completely abolishes calciumsensitive phospholipid binding (Fig. 2C). "
ABSTRACT: Muscle growth occurs during embryonic development and continues in adult life as regeneration. During embryonic muscle growth and regeneration in mature muscle, singly nucleated myoblasts fuse to each other to form myotubes. In muscle growth, singly nucleated myoblasts can also fuse to existing large, syncytial myofibers as a mechanism of increasing muscle mass without increasing myofiber number. Myoblast fusion requires the alignment and fusion of two apposed lipid bilayers. The repair of muscle plasma membrane disruptions also relies on the fusion of two apposed lipid bilayers. The protein dysferlin, the product of the Limb Girdle Muscular Dystrophy type 2 locus, has been shown to be necessary for efficient, calcium-sensitive, membrane resealing. We now show that the related protein myoferlin is highly expressed in myoblasts undergoing fusion, and is expressed at the site of myoblasts fusing to myotubes. Like dysferlin, we found that myoferlin binds phospholipids in a calcium-sensitive manner that requires the first C2A domain. We generated mice with a null allele of myoferlin. Myoferlin null myoblasts undergo initial fusion events, but they form large myotubes less efficiently in vitro, consistent with a defect in a later stage of myogenesis. In vivo, myoferlin null mice have smaller muscles than controls do, and myoferlin null muscle lacks large diameter myofibers. Additionally, myoferlin null muscle does not regenerate as well as wild-type muscle does, and instead displays a dystrophic phenotype. These data support a role for myoferlin in the maturation of myotubes and the formation of large myotubes that arise from the fusion of myoblasts to multinucleate myotubes.Development 01/2006; 132(24):5565-75. DOI:10.1242/dev.02155 · 6.27 Impact Factor
[Show abstract] [Hide abstract]
- "Obviously, many more mutations have to be compiled before genotype/phenotype relationships can emerge. However, other factors and other genes acting as modifiers help explain the clinical heterogeneity in dysferlinopathies (Davis et al., 2000; Illarioshkin et al., 2000; Weiler et al., 1999). Moreover, although classical Miyoshi myopathy and the LGMD2B phenotype are the most prevalent phenotypes associated to DYSF mutations, a spectrum of various phenotypes, ranging from isolated hyperCKaemia, even late in adulthood, to severe proximodistal phenotype have been observed, some of them being specifically reported in the present study. "
ABSTRACT: DYSF encoding dysferlin is mutated in Miyoshi myopathy and Limb-Girdle Muscular Dystrophy type 2B, the two main phenotypes recognized in dysferlinopathies. Dysferlin deficiency in muscle is the most relevant feature for the diagnosis of dysferlinopathy and prompts the search for mutations in DYSF. DYSF, located on chromosome 2p13, contains 55 coding exons and spans 150 kb of genomic DNA. We performed a genomic analysis of the DYSF coding sequence in 34 unrelated patients from various ethnic origins. All patients showed an absence or drastic decrease of dysferlin expression in muscle. A primary screening of DYSF using SSCP or dHPLC of PCR products of each of 55 exons of the gene was followed by sequencing whenever a sequence variation was detected. All together, 54 sequence variations were identified in DYSF, 50 of which predicting either a truncated protein or one amino-acid substitution and most of them (34 out of 54) being novel. In 23 patients, we identified two pathogenic mutations, while only one was identified in 11 patients. These mutations were widely spread in the coding sequence of the gene without any mutational "hotspot."Human Mutation 08/2005; 26(2):165. DOI:10.1002/humu.9355 · 5.05 Impact Factor
[Show abstract] [Hide abstract]
- "Different clinical features were also observed in F2, in which the brother showed proximal dominant muscle involvement, while the sister showed distal myopathy. Although it is unclear as to why clinical features were different among the same family with the same mutation, similar findings have often been observed (Matsumura et al., 1999; Weiler et al., 1999; Illarioshkin et al., 2000; Nakagawa et al., "
ABSTRACT: Mutations in the dysferlin gene (DYSF) on chromosome 2p13 cause distinct phenotypes of muscular dystrophy: limb-girdle muscular dystrophy type 2B (LGMD2B), Miyoshi myopathy (MM), and distal anterior compartment myopathy, which are known by the term 'dysferlinopathy'. We performed mutation analyses of DYSF in 14 Italian patients from 10 unrelated families with a deficiency of dysferlin protein below 20% of the value in normal controls by immunoblotting analysis. We identified 11 different mutations, including eight missense and three deletion mutations. Nine of them were novel mutations. We also identified a unique 6-bp insertion polymorphism within the coding region of DYSF in 15% of Italian population, which was not observed in East Asian populations. The correlation between clinical phenotype and the gene mutations was unclear, which suggested the role of additional genetic and epigenetic factors in modifying clinical symptoms.European Journal of Neurology 11/2004; 11(10):657-61. DOI:10.1111/j.1468-1331.2004.00755.x · 3.85 Impact Factor